References
1
Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
2
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
3
Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-38.
4
Guo L, Fu B, Liu Y, Hao N, Ji Y, Yang H. Diuretic resistance in patients with kidney disease: Challenges and opportunities. Biomed Pharmacother 2023;157:114058.
5
Chitturi C, Novak JE. Diuretics in the Management of Cardiorenal Syndrome. Adv Chronic Kidney Dis 2018;25:425-433.
6
Pellicori P, Kaur K, Clark AL. Fluid Management in Patients with Chronic Heart Failure. Card Fail Rev 2015;1:90-95.
7
de la Espriella R, Santas E, Zegri Reiriz I, Górriz JL, Cobo Marcos M, Núñez J. Quantification and Treatment of Congestion in Heart Failure: A Clinical and Pathophysiological Overview. Nefrologia 2021:S0211-6995(21)00114-4.
8
Palazzuoli A, Evangelista I, Nuti R. Congestion occurrence and evaluation in acute heart failure scenario: time to reconsider different pathways of volume overload. Heart Fail Rev 2020;25:119-131.
9
Cogliati C, Ceriani E, Gambassi G, De Matteis G, Perlini S, Perrone T, et al. Phenotyping congestion in patients with acutely decompensated heart failure with preserved and reduced ejection fraction: The Decongestion duRing therapY for acute decOmpensated heart failure in HFpEF vs HFrEF- DRY-OFF study. Eur J Intern Med 2022;97:69-77.
10
Sharma A, Patel R, Prasad A, Bansal S. Diuretic resistance in acute decompensated HFpEF vs. HFrEF. Clin Nephrol 2023;100:47-50.
11
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-e1032.
12
Schrier RW, Coffman TM, Falk RJ, Molitoris BA, Neilson EG. Schrier’s Diseases of the Kidney 9th Edition. Lippincott Williams & Wilkins (LWW) 2012.
13
Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014;2014:CD003824.
14
REUBI FC, COTTIER PT. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 1961;23:200-210.
15
Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 2012;14:32-37.
16
Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C, Bilancio G. Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension 2014;63:692-697.
17
Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med 2021;385:2507-2519.
18
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229.
19
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-2263.
20
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med 2022;387:1185-1195.
21
Shawkat H, Westwood MM, Mortimer A. Mannitol: a review of its clinical uses. Continuing Education in Anaesthesia Critical Care & Pain 2012;12:82-85.
22
Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O’Brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail 2011;17:973-981.
23
Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail 2011;17:982-989.
24
Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53:283-290.
25
Hodson DZ, Griffin M, Mahoney D, Raghavendra P, Ahmad T, Turner J, et al. Natriuretic Response Is Highly Variable and Associated With 6-Month Survival: Insights From the ROSE-AHF Trial. JACC Heart Fail 2019;7:383-391.
26
Brinkley DM Jr, Burpee LJ, Chaudhry SP, Smallwood JA, Lindenfeld J, Lakdawala NK, et al. Spot Urine Sodium as Triage for Effective Diuretic Infusion in an Ambulatory Heart Failure Unit. J Card Fail 2018;24:349-354.
27
Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57:601-609.
28
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137-155.
29
Hoorn EJ, Wilcox CS, Ellison DH. Diuretics. In: Skorecki K, Chertow G, Marsden P, Taal M, Yu A, editors. Brenner and Rector’s The Kidney. 10. Vol. 2. Philadelphia: Elsevier; 2015. p. 1702-1734.
30
Paterna S, Di Pasquale P, Parrinello G, Amato P, Cardinale A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305-313.
31
Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 2003;284:F1115-F1119.
32
Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, et al. Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. Circ Heart Fail 2016;9:10.1161/CIRCHEARTFAILURE.
33
Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982;72:929-938.
34
Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014;39:171-182.
35
Brady HR, Wilcox CS, editors. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector’s The Kidney. Philadelphia: WB Saunders Company; 1999. p. 672.
36
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
37
Pliquett RU. Cardiorenal Syndrome: An Updated Classification Based on Clinical Hallmarks. J Clin Med 2022;11:2896.
38
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-711.
39
Takahama H, Kitakaze M. Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am J Physiol Heart Circ Physiol 2017;313:H715-H721.
40
Ricci Z, Romagnoli S, Ronco C. Cardiorenal Syndrome. Crit Care Clin 2021;37:335-347.
41
Di Lullo L, Bellasi A, Barbera V, Russo D, Russo L, Di Iorio B, et al. Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J 2017;69:255-265.
42
Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J 2005;26:11-17.
43
Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome--current understanding and future perspectives. Nat Rev Nephrol 2014;10:48-55.
44
Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 2014;35:1284-1293.
45
Casu G, Merella P. Diuretic Therapy in Heart Failure - Current Approaches. Eur Cardiol 2015;10:42-47.
46
He XR, Greenberg SG, Briggs JP, Schnermann J. Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. Hypertension 1995;26:137-142.
47
Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
48
Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-158.
49
Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, et al. Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail 2016;22:753-760.
50
Gupta R, Testani J, Collins S. Diuretic Resistance in Heart Failure. Curr Heart Fail Rep 2019 ;16:57-66.
51
Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005;96:11G-17G.
52
Kazory A. Cardiorenal syndrome: ultrafiltration therapy for heart failure--trials and tribulations. Clin J Am Soc Nephrol 2013;8:1816-1828.
53
Giglioli C, Landi D, Gensini GF, Valente S, Cecchi E, Scolletta S, et al. Cardiac efficiency improvement after slow continuous ultrafiltration is assessed by beat-to-beat minimally invasive monitoring in congestive heart failure patients: a preliminary report. Blood Purif 2010;29:44-51.
54
Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001;38:963-968.
55
Hanna MA, Tang WH, Teo BW, O’Neill JO, Weinstein DM, Lau SM, et al. Extracorporeal ultrafiltration vs. conventional diuretic therapy in advanced decompensated heart failure. Congest Heart Fail 2012;18:54-63.
56
Costanzo MR. Ultrafiltration in Acute Heart Failure. Card Fail Rev 2019;5:9-18.
57
Agostoni PG, Marenzi GC, Pepi M, Doria E, Salvioni A, Perego G, et al. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol 1993;21:424-431.
58
Malbrain MLNG, Martin G, Ostermann M. Everything you need to know about deresuscitation. Intensive Care Med 2022;48:1781-1786.
59
Rosner MH, Ostermann M, Murugan R, Prowle JR, Ronco C, Kellum JA, et al. Indications and management of mechanical fluid removal in critical illness. Br J Anaesth 2014;113:764-771.
60
Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043-2046.
61
Costanzo MR, Saltzberg M, O’Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:2047-2051.
62
Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-683.
63
Giglioli C, Landi D, Cecchi E, Chiostri M, Gensini GF, Valente S, et al. Effects of ULTRAfiltration vs. DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study. Eur J Heart Fail 2011;13:337-346.
64
Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-2304.
65
Grodin JL, Carter S, Bart BA, Goldsmith SR, Drazner MH, Tang WHW. Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF. Eur J Heart Fail 2018;20:1148-1156.
66
Marenzi G, Muratori M, Cosentino ER, Rinaldi ER, Donghi V, Milazzo V, et al. Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail 2014;20:9-17.
67
Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT, Anand IS, et al. Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. JACC Heart Fail 2016;4:95-105.
68
Hu J, Wan Q, Zhang Y, Zhou J, Li M, Jiang L, et al. Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial. BMC Cardiovasc Disord 2020;20:447.
69
Jain A, Agrawal N, Kazory A. Defining the role of ultrafiltration therapy in acute heart failure: a systematic review and meta-analysis. Heart Fail Rev 2016;21:611-619.
70
Wobbe B, Wagner J, Szabó DK, Rostás I, Farkas N, Garami A, et al. Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis. Heart Fail Rev 2021;26:577-585.
71
Jefferies JL, Bartone C, Menon S, Egnaczyk GF, O’Brien TM, Chung ES. Ultrafiltration in heart failure with preserved ejection fraction: comparison with systolic heart failure patients. Circ Heart Fail 2013;6:733-739.
72
Liang KV, Hiniker AR, Williams AW, Karon BL, Greene EL, Redfield MM. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail 2006;12:707-714.
73
Patarroyo M, Wehbe E, Hanna M, Taylor DO, Starling RC, Demirjian S, et al. Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol 2012;60:1906-1912.
74
Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation 2018;137:2016-2028.
75
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, et al. Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. Am J Kidney Dis 2022;80:65-78.
76
Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, et al. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. J Am Coll Cardiol 2017;69:2428-2445.
77
Srivastava M, Harrison N, Caetano AFS, Tan AR, Law M. Ultrafiltration for acute heart failure. Cochrane Database Syst Rev 2022;1:CD013593.
78
Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol 2017;18:69.
79
Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis. Circ Cardiovasc Qual Outcomes 2009;2:566-573.
80
Costanzo MR, Fonarow GC, Rizzo JA. Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis. J Med Econ 2019;22:577-583.
81
Stawicki SP, Braslow BM, Panebianco NL, Kirkpatrick JN, Gracias VH, Hayden GE, et al. Intensivist use of hand-carried ultrasonography to measure IVC collapsibility in estimating intravascular volume status: correlations with CVP. J Am Coll Surg 2009;209:55-61.
82
Bayes-Genis A, Lupón J, Jaffe AS. Can Natriuretic Peptides be Used to Guide Therapy? EJIFCC 2016;27:208-216.
83
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
84
Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990;66:40D-44D.
85
Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int 2019;95:973-982.
86
Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-1444.
87
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102:S1-S127.
88
Boen ST, Mulinari AS, Dillard DH, Scribner BH. PERIODIC PERITONEAL DIALYSIS IN THE MANAGEMENT OF CHRONIC UREMIA. Transactions - American Society for Artificial Internal Organs 1962;8:256-262.
89
Teitelbaum I. Peritoneal Dialysis. N Engl J Med 2021;385:1786-1795.
90
Agre P. Aquaporin water channels (Nobel Lecture). Angew Chem Int Ed Engl 2004;43:4278-4290.
91
Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994;46:1422-1430.
92
Francois K, Ronco C, Bargman JM. Peritoneal Dialysis for Chronic Congestive Heart Failure. Blood Purif 2015;40:45-52.
93
Lu R, Mucino-Bermejo MJ, Ribeiro LC, Tonini E, Estremadoyro C, Samoni S, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med 2015;5:145-156.
94
Nakayama M, Nakano H, Nakayama M. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis. J Cardiol 2010;55:49-54.
95
Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WH. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail 2008;14:508-514.
96
Basile C, Chimienti D, Bruno A, Cocola S, Libutti P, Teutonico A, et al. Efficacy of peritoneal dialysis with icodextrin in the long-term treatment of refractory congestive heart failure. Perit Dial Int 2009;29:116-118.
97
Fourtounas C, Dousdampanis P, Hardalias A, Vlachojannis JG. Sodium removal and peritoneal dialysis modalities: no differences with optimal prescription of icodextrin. Artif Organs 2013;37:E107-E113.
98
Dousdampanis P, Trigka K, Bargman JM. Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients. Int J Nephrol 2013;2013:424915.
99
Kazory A, Koratala A, Ronco C. Customization of Peritoneal Dialysis in Cardiorenal Syndrome by Optimization of Sodium Extraction. Cardiorenal Med 2019;9:117-124.
100
Attaluri V, Lebeis C, Brethauer S, Rosenblatt S. Advanced laparoscopic techniques significantly improve function of peritoneal dialysis catheters. J Am Coll Surg 2010;211:699-704.
101
Cairns KB, Porter GA, Kloster FE, Bristow JD, Griswold HE. Clinical and hemodynamic results of peritoneal dialysis for severe cardiac failure. Am Heart J 1968;76:227-234.
102
Tormey V, Conlon PJ, Farrell J, Horgan J, Walshe JJ. Long-term successful management of refractory congestive cardiac failure by intermittent ambulatory peritoneal ultrafiltration. QJM 1996;89:681-683.
103
Koch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail 2012;14:530-539.
104
Mehrotra R, Kathuria P. Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int Suppl 2006:S67-S71.
105
Núñez J, Gonzales M, Miñana G, Garcia-Ramón R, Sanchis J, Bodí V, et al. Diálisis peritoneal ambulatoria continua y evolución clínica de pacientes con insuficiencia cardiaca congestiva refractaria. Revista EspañOla De Cardiología 2012;65:986-999.
106
Pavo N, Yarragudi R, Puttinger H, Arfsten H, Strunk G, Bojic A, et al. Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. PLoS One 2018;13:e0206830.
107
Xue Y, Xu B, Su C, Han Q, Wang T, Tang W. Cardiorenal syndrome in incident peritoneal dialysis patients: What is its effect on patients’ outcomes? PLoS One 2019;14:e0218082.
108
Grossekettler L, Schmack B, Meyer K, Brockmann C, Wanninger R, Kreusser MM, et al. Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail 2019;6:271-279.
109
Wojtaszek E, Grzejszczak A, Niemczyk S, Malyszko J, Matuszkiewicz-Rowińska J. Peritoneal Ultrafiltration in the Long-Term Treatment of Chronic Heart Failure Refractory to Pharmacological Therapy. Front Physiol 2019;10:310.
110
Al-Hwiesh AK, Abdul-Rahman IS, Al-Audah N, Al-Hwiesh A, Al-Harbi M, Taha A, et al. Tidal peritoneal dialysis versus ultrafiltration in type 1 cardiorenal syndrome: A prospective randomized study. Int J Artif Organs 2019;42:684-694.
111
Sahlie A, Jaar BG, Paez LG, Masud T, Lea JP, Burkart JM, et al. Burden and Correlates of Hospital Readmissions among U.S. Peritoneal Dialysis Patients. Perit Dial Int 2019;39:261-267.
112
Sun CY, Sung JM, Wang JD, Li CY, Kuo YT, Lee CC, et al. A comparison of the risk of congestive heart failure-related hospitalizations in patients receiving hemodialysis and peritoneal dialysis - A retrospective propensity score-matched study. PLoS One 2019;14:e0223336.
113
Chionh CY, Clementi A, Poh CB, Finkelstein FO, Cruz DN. The use of peritoneal dialysis in heart failure: A systematic review. Perit Dial Int 2020;40:527-539.
114
van der Meer P, Gaggin HK, Dec GW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll Cardiol 2019;73:2756-2768.
115
Sugiura E, Dohi K, Tanimura M, Kumagai N, Ishikawa E, Ito M. Successful Peritoneal Dialysis for the Treatment of Inotrope-Dependent End-Stage Heart Failure. Int Heart J 2019;60:1211-1218.
116
Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-371.
117
Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail 2017;19:1427-1443.
118
Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. Cochrane Database Syst Rev 2019;1:CD002752.
119
Lewin J, Ledwidge M, O’Loughlin C, McNally C, McDonald K. Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 2005;7:953-957.
120
Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008;51:1073-1079.
121
Adamson PB, Abraham WT, Aaron M, Aranda JM Jr, Bourge RC, Smith A, et al. CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. J Card Fail 2011;17:3-10.
122
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-666.
123
Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014;7:935-944.
124
Heywood JT, Jermyn R, Shavelle D, Abraham WT, Bhimaraj A, Bhatt K, et al. Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. Circulation 2017;135:1509-1517.
125
Desai AS, Bhimaraj A, Bharmi R, Jermyn R, Bhatt K, Shavelle D, et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in “Real-World” Clinical Practice. J Am Coll Cardiol 2017;69:2357-2365.
126
Vaduganathan M, DeFilippis EM, Fonarow GC, Butler J, Mehra MR. Postmarketing Adverse Events Related to the CardioMEMS HF System. JAMA Cardiol 2017;2:1277-1279.
127
Schmier JK, Ong KL, Fonarow GC. Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System. Clin Cardiol 2017;40:430-436.
128
Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 2010;121:1086-1095.
129
Abraham WT, Adamson PB, Costanzo MR, Eigler N, Gold M, Klapholz M, et al. Hemodynamic monitoring in advanced heart failure: results from LAPTOP-HF trial. J Card Fail 2016;22:P940.
130
Abraham WT, Compton S, Haas G, Foreman B, Canby RC, Fishel R, et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail 2011;17:51-55.
131
Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J 2011;32:2266-2273.
132
van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, et al. ntrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011;124:1719-1726.
133
Adamson PB, Gold MR, Bennett T, Bourge RC, Stevenson LW, Trupp R, et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail 2011;17:248-254.
134
Böhm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, et al. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J 2016;37:3154-3163.
135
Whellan DJ, Ousdigian KT, Al-Khatib SM, Pu W, Sarkar S, Porter CB, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol 2010;55:1803-1810.
136
Landolina M, Perego GB, Lunati M, Curnis A, Guenzati G, Vicentini A, et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 2012;125:2985-2992.
137
Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014;384:583-590.
138
Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991-1001.
139
Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet 2023;401:2113-2123.
140
Zito A, Princi G, Romiti GF, Galli M, Basili S, Liuzzo G, et al. Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2022;24:2333-2341.
